Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer by Stephan Gade et al.
RESEARCH ARTICLE Open Access
Graph based fusion of miRNA and mRNA
expression data improves clinical outcome
prediction in prostate cancer
Stephan Gade1*, Christine Porzelius2, Maria Fälth1, Jan C Brase1, Daniela Wuttig1, Ruprecht Kuner1, Harald Binder4,2,
Holger Sültmann1 and Tim Beißbarth3*
Abstract
Background: One of the main goals in cancer studies including high-throughput microRNA (miRNA) and mRNA
data is to find and assess prognostic signatures capable of predicting clinical outcome. Both mRNA and miRNA
expression changes in cancer diseases are described to reflect clinical characteristics like staging and prognosis.
Furthermore, miRNA abundance can directly affect target transcripts and translation in tumor cells. Prediction
models are trained to identify either mRNA or miRNA signatures for patient stratification. With the increasing
number of microarray studies collecting mRNA and miRNA from the same patient cohort there is a need for
statistical methods to integrate or fuse both kinds of data into one prediction model in order to find a combined
signature that improves the prediction.
Results: Here, we propose a new method to fuse miRNA and mRNA data into one prediction model. Since
miRNAs are known regulators of mRNAs we used the correlations between them as well as the target prediction
information to build a bipartite graph representing the relations between miRNAs and mRNAs. This graph was
used to guide the feature selection in order to improve the prediction. The method is illustrated on a prostate
cancer data set comprising 98 patient samples with miRNA and mRNA expression data. The biochemical relapse
was used as clinical endpoint. It could be shown that the bipartite graph in combination with both data sets could
improve prediction performance as well as the stability of the feature selection.
Conclusions: Fusion of mRNA and miRNA expression data into one prediction model improves clinical outcome
prediction in terms of prediction error and stable feature selection. The R source code of the proposed method is
available in the supplement.
Background
High throughput techniques, such as gene expression
arrays, have made it possible to identify biomarkers and
gene signatures for a wide range of diseases. For breast
cancer several gene signatures have been proven to have
a prognostic value [1-3]. Based on these, multigene tests
like MammaPrint and Oncotype DX have found their
way into clinical practice [4]. However, the efforts in
using gene expression data to stratify cancer patients
unraveled general limitations. Prognostic or predictive
signatures are often restricted to a subset of patients
which meet specific inclusion criteria like epidemiologi-
cal, histopathological and clinical characteristics. Further-
more, gene expression data alone often did not reflect
robust molecular subtypes in other cancer entities. For
example in prostate cancer, one of the most frequent
cancer types among men [5], the robust molecular diag-
nosis of a clinical relevant disease is still a challenge [6].
Genome scale experiments measure thousands up to
millions of features. To be able to build clinical prediction
models with these data, methodology from the field of
machine learning is applied. Popular methods include
SVM [7], Random Forests [8], and certain boosting
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approaches [9]. A particular challenge is the high number
of features in the training data, especially if the correlation
structure among the measured features is unknown.
Therefore, the training results often remain unsatisfactory.
In the past, integration of other sources of data that lead
to an improved feature selection and thus to a better gen-
eralization of the prediction model has been discussed.
Recent methods have integrated estimates of the correla-
tion structure of the data based on prior information
represented as graphs. The graph was gained from biologi-
cal knowledge on interactions between genes or member-
ship of genes to common pathways [10-15]. Other
methods have integrated different kind of omics data [16].
When integrating data from different levels, properties
and scales have to be taken into account as well as the
relations between the different types of features.
Here, we propose a new method to fuse gene expression
data with microRNA (miRNA) expression data into one
risk prediction model. miRNAs are small, around 22 base
pairs long, non-coding RNAs that regulate gene expression
post-transcriptionally. By sequence mediated binding of
the miRNA to its target, the translational process is
blocked or the mRNA is predisposed to degradation.
Deregulation of miRNAs has been linked to development
and progression of several tumor entities including pros-
tate cancer [17-20]. Because of their regulatory nature, the
primary targets of a miRNA are of particular interest.
Since experimentally validated targets are rare, target pre-
diction algorithms are an important source of knowledge
when dealing with miRNA expression data. Several algo-
rithms and databases for miRNA target predictions have
been established in the last years including e.g. miRanda
[21], TargetScan [22], and PicTar [23].
Our new method uses a bipartite graph combining cor-
relations between miRNA and gene expression data, and
target prediction information. This gave rise to better pre-
diction results compared to the single data sets in a pros-
tate cancer data set encompassing 98 tumor samples.
The manuscript is organized as follows. The first sec-
tion describes the general setup including high-dimen-
sional time-to-event data and the measure of prediction
error as well as the prediction methods. In the results
part the final workflow is explained in detail and the per-
formance on the prostate cancer data set is shown. Com-
parisons with two other prediction methods suited for
time-to-event data are shown as well. The manuscript
closes with a discussion and conclusion.
Methods
Setup
High dimensional time-to-event data
Time-to-event data, such as survival data, is typically
modeled using the Cox proportional hazards model [24]
of the form
h (t|xi) = h0 (t) exp (ηi) (1)
with an unspecified baseline hazard h0(t) and a linear
predictor
ηi = xiTβ (2)
Usually, observations are of the form (t1, δ1, x1), ..., (tn,
δn, xn) where ti is an observed time, δi a censoring indi-
cator (1 indicates an event while 0 indicates censoring),
and xi = (x1, ..., xp) a feature vector. The Cox model
describes the instantaneous risk of having an event at a
given time point t. In a high-dimensional setting xi and
thus b comprises several thousands of features, most of
them irrelevant for predicting h(t|x). Therefore, it is rea-
sonable to assume most of the entries in b to be 0 and
methods with an implicit feature selection are
preferable.
Prediction error curves and IPEC
The estimation of the Cox parameter vector βˆ can be
used to obtain a risk prediction







with the Breslow estimator of the cumulative baseline
hazard Hˆ0(t) =
∫ t
0 h0(s)ds . The predicted probability
rˆ (t|xi) of still being event-free at time t can be seen as
predicting the true status I(ti > t). To assess the quality
of these predictions the Brier score
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can be used [25], describing the average discrepancy
between the event states and the model predictions.
Due to censoring, inverse probability of censoring
weights have to be used to obtain consistent estimates
of (4). By tracking this empirical version of the Brier
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where Gˆ is the Kaplan-Meier [26] estimate for the
censoring distribution G [25] (cf. Figure 1). By integra-
tion over time the integrated prediction error curve
(IPEC) is obtained. Here the R-package peperr [27,28]
was used for assessment of model predictions.
Estimation of prediction error
To estimate the prediction performance (and compare it
among different models) for new patients without the
need to set aside test data the .632 bootstrap estimator
[29] was used. For every bootstrap sample the .632
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estimator of the prediction error curve was calculated
leading to the IPEC.
Prediction Methods
Boosting
Boosting belongs to the class of ensemble learners. The
basic principle of boosting is the weighted combination
of several weak classifiers in order to build one strong
classifier [9]. This is equal to iteratively fit an additive
model in function space by minimizing a loss function
[30].
Componentwise likelihood-based boosting [31] uses a
penalized log-likelihood criterion to fit the objective
function. In every step only one element of the parameter
vector b is updated which in fact is an implicit feature
selection and results in sparse fits. Since the objective
function is rather general the idea can be extended to
high-dimensional time-to-event data [32]. First, the para-
meter vector is initialized to βˆ0 = (0, ..., 0) . In each
boosting step k (k = 1, ..., M) a new candidate model is
obtained for every covariate j = 1, ..., p
ηˆij,k = ηˆi,k−1 + γj,kxij (6)
with the linear predictor from the previous step
ηˆi,k−1 = xiT , βˆk−1 (7)
For obtaining parameter estimates γˆj,k a penalized
partial log-likelihood is maximized that incorporates a
penalty parameter lj, k which controls the size of the
step. The element of the parameter vector βˆk−−1,j∗ , cor-
responding to that covariate that maximizes the (pena-
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Figure 1 Comparison of Prediction Error Curves. The figure shows the prediction error curves of CoxBoost models trained on the mRNA and
miRNA data. The prediction model was trained with and without the bipartite graph describing the relations between the features. The
incorporation of the graph resulted in a reduction of the prediction error. The .632 estimation of the prediction error was used in this plot,
averaging over the 500 bootstrap samples. As a reference the prediction error of the Kaplan-Meier estimator is shown.
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βˆk,j∗ = βˆk−1,j∗ + γˆj∗,k (8)
All other elements of the parameter estimation remain
unchanged (and therewith zero in most cases). The
number of boosting steps M is a tuning parameter
which needs to be optimized e.g. via cross-validation.
Usually, a common penalty parameter l = lj, k is used
for all covariates and boosting steps. It should be chosen
in a way the resulting number of boosting steps is larger
than 50 [15]. In this study the CoxBoost R-package [33]
was used to train the CoxBoost models.
Lasso
Lasso [34,35] is a shrinkage method for regression mod-
els [[36], chap. 3] with implicit feature selection based
on an L1 penalty term
βˆ = argmax(l(β) − α||β||1) (9)
with a likelihood function l(b). Originally, quadratic
programming was proposed to solve (9) for linear
regression models [34]. Since the solution for Cox pro-
portional hazard models is much more computationally
intensive, Goeman proposed a solution of the Lasso esti-
mation based on gradient ascent optimization [37]. In
this paper the R-package penalized [38] was used to fit
the Lasso estimator.
Random survival forests
A third method is based on decisions trees. Random sur-
vival forests [39] (RSF) is an extension of the Random
forests [8] for right censored survival data. A collection
of binary decision trees is build by bootstrap samples. In
every tree at every node a random subset of m features is
chosen. The survival difference between the daughter
nodes is used to choose a feature and a split point. The
R-package randomSurvivalForest [40] was used to train
the model. The optimal value of m was determined via
bootstrap [27,41] using the peperr R-package [28].
Prostate cancer data set
A prostate cancer data set from Taylor et al. [42] was
used in this study. Raw expression data from Affymetrix
Human Exon 1.0 ST arrays were obtained from the NCBI
GEO data repository (GEO accession number GSE21034)
comprising 131 samples of tumor patients. Furthermore,
miRNA expression data from the Agilent microRNA V2
were downloaded (GEO accession number GSE21036)
including 113 samples of tumor patients.
Data preprocessing
Gene expression profiles were derived from the CEL files
using Robust Multichip Average (RMA) [43] implemen-
ted in the Affymetrix Power Tools (APT). Raw data files
from miRNA expression data were analyzed using the
limma R-package [44]. After quantile normalization [45]
control probes were removed and the 16 replicates of
each miRNA were summarized using the sample-wise
median. At the end only tumor samples with gene
expression as well as miRNA expression data were used
yielding a data matrix with 98 tumor samples, 17881
transcripts, and 723 miRNAs.
BCR status
Clinical parameters of the patients samples were down-
loaded from the supplemental material [42]. The time to
biochemical relapse (BCR) and the censoring status for
98 cancer patients were available. Of these 98 patients
18 suffered a relapse and 80 were censored.
miRNA-target predictions
Target predictions were downloaded from MicroCosm
targets [21,46] (formerly miRBase Targets) version 5.
The p-values of these predictions were extracted for
every miRNA-transcript pair (the transcripts were given
as Ensembl transcript identifiers). For comparison the
TargetScan 5.2 predictions [22] were downloaded.
Results
Graph-based integration of miRNA and mRNA expression
data
The first step in the workflow (Figure 2) was the crea-
tion of the bipartite graph describing the relations
between mRNAs and miRNAs. The first source of
knowledge were both expression data sets coming from
the same samples. The expression vectors from each
mRNA mi and each miRNA mij were correlated using
the Pearson correlation r(mi, mij). The correlation coef-
ficient can be tested for a significant shift from zero
leading to a p-value for every mRNA-miRNA pair
pcori,j = P(H0 : ρ(mi,mij) = 0)
∀i ∈ {1, p1}, j ∈ {1, p2}
(10)
Since many tests (p1 × p2) were performed, the result-
ing p-values were corrected for multiple testing [47] (in
the following pcori,j refers to the corrected values). The
second source of knowledge were the target predictions
from MicroCosm [21]. The p-values ppredi,j of these pre-
diction were used to strengthen the importance of the
connection of a mRNA mi and a certain miRNA mij in
the case where mi is a predicted target of mij. Since the
MicroCosm target database holds only mRNA-miRNA
pairs with a p-value below 0.05 the p-values of pairs not
present in MicroCosm were set to 1.
In order to integrate the two sources of knowledge
both types of p-values had to be combined. This was
done using the method of Stouffer [48,49] leading to
combined p-values
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Figure 2 Workflow Diagram. Workflow of the integration of miRNA and mRNA expression data.
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targets the combined p-values were set to the correla-
tion p-values.
The resulting p-values were well distributed and could
easily be transformed to weights
wi,j = 1 − pcombi,j (12)
The resulting matrix of weights W = wi, j could be
viewed as the p1 × p2 adjacency matrix of a bipartite graph
describing the relations between mRNAs and miRNAs.
The graph W was interpreted as a directed graph with
edges from mRNAs to miRNAs. In conjunction with Cox-
Boost the graph was used to improve the prediction of
time-to-event data. Binder et al. [15] introduced likeli-
hood-based boosting as a possibility to incorporate gene-
gene interaction networks into feature selection in order
to improve the prediction performance. The basic idea
was to increase the penalty parameter lj*,l, l > k after











At the same time the penalty of connected features
was reduced in the following steps
λj+,km+1 =
Ij+,km+1
1 − (1 − Ij+,kmIj+,km+λj+,km )cf
−Ij+,km+1
(14)
Ij+,km is the Fisher information in boosting step km
where the feature was updated the mth time. This
increased the probability of choosing connected features
in future steps, leading to feature sets which were con-
sistent with the given a priori information. By what
amount the penalty of a selected feature was increased
and the penalties of connected features were decreased
was determined by a stepsize modification factor cf.
Similar to graphs describing biological pathway knowl-
edge the mRNA-miRNA graph W described the regula-
tions among the features. Every time an mRNA mi was
picked the penalties l of miRNAs connected to mi were
lowered according to the weight of the connection. As a
consequence it was more likely to choose a miRNA mij
highly correlated and being a predicted regulator of mi
in one of the next boosting steps. miRNAs with a con-
nection with high weight to mi are likely to be a direct
regulator of mi and therefore of importance for the
event as well. The stepsize modification factor was set
to a fixed value of 0.9 for all boosting runs.
Graph information reduces prediction error of CoxBoost
In order to test performance of our new method it was
tested using a prostate cancer data set [42] with mRNA
and miRNA expression data sets from 98 patients using
the biochemical relapse as clinical endpoint. The bipar-
tite graph improved the accuracy of CoxBoost by
increasing the probability of selecting miRNAs with con-
nections to already chosen mRNAs (Figure 1). To
demonstrate this CoxBoost was trained on both data
sets, not given the graph information, and on the single
data sets. To assure a comparability of the prediction
models a common penalty of 1296 was determined such
that the number of boosting steps exceeds 50 in every
case (Table 1). The accuracy of the risk prediction mod-
els were compared by calculating the .632 estimator of
the prediction error curve and its IPEC for 500 boot-
strap samples. The medians of the resulting 500 IPECs
and their interquartile ranges (IQRs) can be seen in
Table 1. To test whether the difference of the IPECs is
significant, a one-sided Wilcoxon test was carried out
between the single models without a graph and the
model incorporating the bipartite graph. It can be seen
that CoxBoost performed best when given both data
sets and the bipartite graph. For every three risk predic-
tion models without graph information the difference
was significant assuming a significance level of 0.05.
There was no difference between the models trained
only on the mRNAs and the model trained on both data
sets without the graph. CoxBoost with only the miRNA
expression data seemed to perform slightly worse.
Comparison with other methods
The CoxBoost model was compared with other methods
suited for time-to-event data. The afore introduced Lasso
and RSF were trained on the same end point given mRNA
data as well as miRNA data. The prediction error was cal-
culated using the same 500 bootstrap samples as before
yielding 500 IPECs for every method. Table 2 shows the
distribution of the IPECs of Lasso and RSF compared to
the IPECs of CoxBoost with graph information. To test
the significance of the differences a one-sided Wilcoxon
test was used. On this data set Lasso and RSF performed
significantly worse than CoxBoost with graph information
assuming a significance level of 0.05. Besides the
Table 1 Comparison of Boosting Results.
M IPEC (median) IQR p-value
only miRNA 98 5.90 0.88 <0.001
only mRNA 100 5.82 0.87 <0.001
both no graph 99 5.79 0.86 <0.001
both with graph 99 5.46 1.20 -
The table shows the number of boosting steps M for every CoxBoost model
and the IPEC (median and IQR) of 500 bootstrap runs. The number of
boosting steps were determined using the whole data set. Lower IPEC scores
indicate better prediction accuracy. The p-value is the result of a one-sided
Wilcoxon test (unpaired) comparing the single data set prediction models and
the prediction model without graph with the combination incorporating the
bipartite graph.
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prediction error there was a remarkable difference in the
runtime of the three models. Training and prediction for
500 bootstrap samples took 40.17 hours for RSF, 2:25
hours for Lasso, and 1:16 hours for CoxBoost with graph
on a 20 core (2.7 GHz) machine with 64 GB memory.
Graph information improves stability of feature selection
In addition to a reduction of the prediction error the
incorporation of the graph information improved the sta-
bility of the feature selection process remarkably. Table 3
lists the top 10 features of CoxBoost with and without the
graph according to the number of bootstrap samples the
features were chosen in. The numbers are almost twice as
large when including the graph information.
Another difference lies in the balance of genes and miR-
NAs picked by the models. While the number of genes
and miRNAs among the top ten features using CoxBoost
without graph were almost equal, in the list of CoxBoost
with graph information there were only miRNAs.
Robustness considerations
Additionally, to exclude the possibility of overfitting the
models were trained with a graph which was build sepa-
rately for every single bootstrap sample. Therefore the cor-
relations were calculated and tested solely on the patient
samples included in the bootstrap sample. In this case the
prediction error increased to 5.64 (median of 500 boot-
strap samples) with an IQR of 0.99. In comparison with
the IPECs of CoxBoost without graph the prediction error
was significant smaller assuming a significance level of
0.05 (p-value from one-sided Wilcoxon test: 0.006). The
runtime increased to 21:36 hours.
To asses the influence of the target prediction database
one graph was constructed using TargetScan in the ver-
sion 5.2. As a p-value for a miRNA-mRNA pair 1 - PCT
was used. The PCT value given in the TargetScan flatfiles
is a score that can be used to asses the biological relevance
of predicted miRNA-mRNA interactions [22]. 1 - PCT is
an estimate of the FDR. CoxBoost using this graph yielded
a median IPEC of 6.60 with an IQR of 0.95.
Discussion
Due to their role as post-transcriptional regulators of
around 30% of the human genome and their involvement
in cancer development and progression [17,18,20,50], miR-
NAs become more and more important for our under-
standing of the mechanisms leading to cancer. Since
miRNAs are smaller than mRNAs they are more stable
and in general more resistant against degradation pro-
cesses than the longer mRNAs. Consequently, miRNA
expression is measurable even in serum [51] and paraffin-
embedded samples where mRNA expression is hardly
detectable.
Several studies have combined gene and miRNA expres-
sion data [52,53] or gene expression data with miRNA tar-
get predictions [54] to infer new miRNA regulation
activities. In addition, several tools have been developed to
integrate such data [55,56]. In most cases, correlations
between mRNA and miRNA expression profiles gained
from matched samples and target prediction scores are
most relevant for the analysis.
While there are several approaches to integrate mRNA
and miRNA data to discover novel regulatory relation
between miRNAs and mRNAs there is still a lack of pre-
diction methods combining both kinds of data into one
common prediction model. A central problem in these
high-dimensional data is the tendency to overfit. When
integrating several omics data sets the number of features
increases, which makes the feature selection even more
important.
In this article we introduce a method capable to fuse
mRNA and miRNA expression data in a model to predict
a clinical endpoint. Likelihood boosting was used as a
method for fitting risk prediction models because of its
performance and its ability to implicitly select features in
the training process. The correlations between miRNAs
and mRNAs and target prediction information were used
to model the relations between miRNAs and mRNAs. The
combination between these two sources of information
Table 2 Comparison with Other Methods.
IPEC (median) IQR p-value
Lasso 6.10 1.12 <0.001
RSF 5.66 0.78 <0.001
CoxBoost with graph 5.46 1.20 -
The table shows the comparison of Lasso and RSF with CoxBoost with the
bipartite graph regarding the prediction error. As before the median and IQR
from 500 IPECs were calculated. The p-value is based on a one-sided
Wilcoxon test comparing the 500 IPECs of Lasso and RSF with the IPECs of
CoxBoost.
Table 3 Selected Features.
No graph With graph
Feature Counts Feature Counts
ESM1 161 hsa-miR-513a-3p 329
hsa-miR-412 151 hsa-miR-513a-5p 316
INHBA 130 hsa-miR-128 249
COMP 126 hsa-miR-1226* 233
ZFHX4 114 hsa-miR-1231 209
SLC6A14 103 hsa-miR-1224-5p 206
hsa-miR-484 92 hsa-miR-220a 199
PI15 83 hsa-miR-1233 198
hsa-miR-556-3p 79 hsa-miR-208a 169
hsa-miR-409-3p 74 hsa-miR-199b-3p 168
The table lists the top ten features from CoxBoost with and without graph
information. mRNA names are given by their gene symbols (capital letters)
while miRNA names are given by their miRBase IDs (starting with hsa-miR).
The Counts columns indicate in what number of the 500 bootstrap samples
the feature was chosen. Consequently, the maximal count would be 500.
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was performed on a p-value level using the method from
Stouffer [48]. From the combined p-values a bipartite
graph could be constructed covering the relations between
the two types of features.
The integration of this graph into boosting improves the
models in terms of prediction error. In this case the clini-
cal endpoint was the biochemical relapse in prostate can-
cer using a combined miRNA/mRNA data set of 98
patients [42]. The comparisons of the IPECs clearly
showed a significant reduction of the prediction error in
comparison with boosting on the single data sets or on the
combined data set without the bipartite graph. Here we
used the .632 bootstrap estimator of the prediction error
because of its simplicity. Other estimators like the .632+
estimator [57] are often used for prediction error estima-
tion for survival models [15,41,58]. It might be less biased
but computationally more expensive. First tests with the
.632+ estimator lead to comparable results.
Using the graph the feature selection became more
stable regarding how often a specific feature was picked in
the 500 bootstrap runs. By transferring the weights in the
graph from mRNAs to miRNAs, these features were
favored. However, it is important to note that miRNA
expression data alone failed to predict the relapse as accu-
rate as the combined data with the graph. This may be
caused by the fact that one miRNA can have several tar-
gets and dysregulation of a miRNA can affect multiple
molecular pathways with no direct connection to the out-
come. Therefore, the genes as effectors seem to be a man-
datory source of information. Among the top 10 features
picked using the graph there are some miRNAs found to
play a role in prostate cancer, e.g. hsa-miR-128 [59]. How-
ever, most of the miRNAs have not been associated with
prostate cancer before. It is therefore important to note
that it is not straightforward to derive functional implica-
tions for single biomarkers from a panel found by a pre-
diction model. The strength of our method is to find
miRNA-gene combinations with high predictive power.
To investigate whether the selected genes show differences
in functional annotations, we also performed a GO enrich-
ment test for the top 100 genes of CoxBoost with and
without graph (data not shown). Both sets showed differ-
ent enriched GO terms. However, no clear patterns con-
cerning cancer related processes occurred.
To assess how our method performed in comparison
with other methods suited for time-to-event data, Lasso
and RSF were tested on the same data set using the same
bootstrap samples. In both cases CoxBoost with the bipar-
tite graph showed a significantly lower prediction error.
RSF performed better than Lasso which was worse than
CoxBoost without graph on this data set. The runtime of
RSF and Lasso was considerably longer than the runtime
of CoxBoost with graph on our test system. In this study
we used the standard implementations of Lasso and RSF
as a reference. As far as we know there are no established
ways to combine Lasso or RSF with a graph to guide the
feature selection. It might be interesting to see if such
methods will improve the prediction error as well. Also
other ways of fusing miRNA and mRNA expression data
into one model e.g. bundling [60] or kernel based methods
[16] have not been considered. Such methods offer a very
flexible way of combining different prediction models and
might also lead to improvements in terms of prediction
error.
To minimize the possibility of overfitting, one CoxBoost
model was trained with correlations calculated only on the
training data of every bootstrap sample. The resulting pre-
diction error is higher compared to the models with corre-
lations calculated once on the whole data set but it is still
significantly lower than CoxBoost with no graph. Further,
we showed that the prediction could be improved using
the target prediction information from MicroCosm. In
order to test the influence of the target prediction database
we also tried to incorporate the target predictions from
TargetScan. This resulted in a higher prediction error,
however. This result can possibly be explained by the
lower coverage of TargetScan. From the 723 miRNAs in
the data set only 170 could be found in TargetScan having
a PCT value. In comparison, the MicroCosm predictions
contained 698 out of the 723 miRNAs with p-values.
While miRNA and mRNA expression data gained from
microarray experiments were used in this study, the
method is independent of the underlying experimental
setup. Next generation sequencing data might be, after the
necessary preprocessing steps, used in a similar manner.
We presented the fusion of the both data sets with respect
to a prognostic time-to-event endpoint. However, in a
similar fashion binary endpoints like diagnostic questions
or treatment response prediction can be tackled. This
would lead to classification problems for which boosting
was originally designed and powerful approaches have
been formulated. On our setting we would substitute the
CoxBoost algorithm by GAMBoost [61].
Conclusions
With the increasing availability of high-throughput data
on many different layers of biological regulation, the inte-
gration and fusion of these data sets becomes a key con-
cept when analyzing complex diseases. Combined
prediction models involving mRNA and miRNA expres-
sion data should include the relations between the differ-
ent features in the model.
In this article we propose a new method to fuse miRNA
and mRNA expression data in a risk prediction model to
stratify the risk of a biochemical relapse of prostate cancer
patients. In our new approach we combine the CoxBoost
model with a bipartite graph assembled from correlations
between miRNAs and mRNAs and target prediction
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information from MicroCosm targets. Using this graph an
improvement of the risk prediction could be achieved.
Besides an improved risk prediction we could show that
the feature selection became more stable and therewith
easier to interpret. CoxBoost with graph performed signifi-
cantly better than two other methods suited for time-to-
event data.
The R source code of the proposed method is avail-
able in the supplement (see Additional file 1).
Additional material
Additional file 1: R Code. The additional file supp1.r contains the R
functions for the proposed workflow of integrating mRNA and miRNA
expression data.
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